Hematology

Biology, Misdiagnosis & Getting the Right Answer

At a Glance

TRMA is an inherited disorder caused by changes in both copies of SLC19A2. It can cause megaloblastic anemia, hearing loss, and non-autoimmune diabetes, mimic other conditions, and is confirmed by genetic testing that identifies both disease-causing changes.

The biology of Thiamine-Responsive Megaloblastic Anemia (TRMA) is a story of a missing “doorway.” While most people can easily move thiamine (Vitamin B1) from their bloodstream into their cells, children with TRMA lack the specific equipment needed to perform this task in certain parts of the body ^[1]^[2].

The Role of SLC19A2 and THTR1

Your child’s diagnosis is caused by a change in a gene called SLC19A2 ^[3]. This gene is responsible for creating a protein called THTR1 ^[1]. Think of THTR1 as a high-speed, specialized doorway (a thiamine transporter) that allows thiamine to enter cells so they can produce energy ^[4]^[2].

TRMA is an autosomal recessive condition ^[5]. This means a child must inherit two changed versions of the SLC19A2 gene—one from each parent—to develop the disorder ^[6]^[7]. Parents are typically “carriers,” meaning they have one changed gene and one working gene, which is enough to keep them healthy ^[6]. If both parents are confirmed carriers, each pregnancy has a 25% chance of the child having TRMA, a 50% chance of the child being a carrier, and a 25% chance of being unaffected. Siblings may need evaluation and genetic counseling, as symptoms can develop later.

Why Certain Parts of the Body Struggle

You may wonder why TRMA affects the blood, ears, and pancreas specifically. While the body has a second “doorway” (THTR2) that works in many organs, the bone marrow, the pancreas, and the cochlea (inner ear) rely almost exclusively on the THTR1 doorway ^[4]^[3].

When THTR1 doesn’t work:

Bone Marrow: Cells cannot produce healthy red blood cells, leading to large, fragile cells (megaloblasts) ^[8]^[9].
Pancreas: The cells that make insulin (beta cells) experience “stress” and eventually stop working because they lack the energy provided by thiamine ^[10]^[11].
Inner Ear: The delicate hair cells in the ear cannot survive without a constant supply of thiamine, leading to hearing loss ^[3]^[12].

Common Misdiagnoses

Because TRMA is so rare, it is frequently mistaken for more common conditions during the early stages of the diagnostic journey.

The Anemia Confusion

TRMA anemia is often misidentified as Myelodysplastic Syndrome (MDS), a serious condition involving abnormal bone marrow ^[8]^[13]. Because both conditions can show “dysplastic” or oddly shaped cells in the marrow, the distinction is critical ^[8]. TRMA is also sometimes mistaken for forms of Sideroblastic Anemia, a group of disorders where abnormal iron accumulation occurs in the mitochondria of erythroid precursors (red blood cell precursors) in the bone marrow, forming ring sideroblasts ^[9]^[14].

The Diabetes Confusion

The diabetes in TRMA is often initially treated as standard Type 1 or Type 2 diabetes ^[15]. However, TRMA-related diabetes is different: it is non-autoimmune, meaning the body is not attacking itself ^[16]^[17].

Getting the Right Answer

Doctors use several specific clues to separate TRMA from other conditions, though these are supportive clues rather than absolute rules:

Normal Vitamin Levels: In typical megaloblastic anemia, Vitamin B12 or Folate levels are low. In TRMA, B12 and Folate levels are generally normal ^[8]^[18]. Nutritional deficiencies can, however, coexist.
Negative Antibodies: Unlike Type 1 diabetes, children with TRMA usually test negative for the autoantibodies that characterize autoimmune diabetes ^[16]^[17].
The Thiamine Test: A rapid improvement in anemia after starting high-dose thiamine is a strong supportive clue, but does not definitively confirm TRMA ^[8]^[18]^[19].
Genetic Testing: The true confirmation of TRMA relies on finding biallelic pathogenic or likely pathogenic variants in the SLC19A2 gene ^[5]^[20]. This is typically done through targeted genetic testing or whole-exome sequencing (though standard exome sequencing can miss some variant types).

Common questions in this guide

What causes thiamine-responsive megaloblastic anemia syndrome?

TRMA occurs when a child inherits disease-causing changes in both copies of the SLC19A2 gene, usually one from each parent. SLC19A2 makes THTR1, a transporter that helps vitamin B1, or thiamine, enter cells. Bone marrow, insulin-producing pancreatic cells, and inner-ear cells are especially affected when this transporter does not work.

Why can TRMA be mistaken for myelodysplastic syndrome or sideroblastic anemia?

TRMA can produce abnormal-looking blood-forming cells in the bone marrow, which may resemble myelodysplastic syndrome or sideroblastic anemia. The combination of megaloblastic anemia, hearing loss, and non-autoimmune diabetes can provide an important clue. Normal B12 and folate levels and response to thiamine may support TRMA, but they do not replace genetic confirmation.

Which laboratory results may point toward TRMA?

Normal B12 and folate levels can point away from nutritional megaloblastic anemia, although deficiencies can occur at the same time. Negative diabetes autoantibodies can point away from autoimmune type 1 diabetes. These findings are supportive clues, not absolute rules.

How is TRMA confirmed by genetic testing?

TRMA is confirmed by finding pathogenic or likely pathogenic changes in both copies of SLC19A2. Testing may be targeted to the gene or included in whole-exome sequencing, but standard exome testing can miss some types of changes. A genetics professional can explain whether the reported variants are disease-causing.

How is TRMA-related diabetes different from type 1 diabetes?

TRMA-related diabetes is non-autoimmune, meaning the immune system is not attacking the insulin-producing cells in the way it does in type 1 diabetes. It results from stress and loss of function in pancreatic beta cells when thiamine transport is impaired. It may initially be treated or labeled as type 1 or type 2 diabetes.

Does a quick response to thiamine prove that a child has TRMA?

A rapid improvement in anemia after high-dose thiamine is a strong clue that supports TRMA. However, response to thiamine alone does not definitively confirm the syndrome. Genetic testing is needed to establish the diagnosis.

What is the chance that another child will have TRMA?

If both parents are confirmed carriers of a changed SLC19A2 gene, each pregnancy has a 25% chance of TRMA, a 50% chance of being a carrier, and a 25% chance of being unaffected. Siblings may need evaluation because symptoms can develop later, and genetic counseling can help interpret the family's results.

Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2.
Enogieru OJ, Koleske ML, Vora B, et al.
The AAPS journal 2021; (23(2)):35 doi:10.1208/s12248-021-00562-4.
PMID: 33649974
2
Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies.
Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, et al.
Journal of inherited metabolic disease 2019; (42(4)):581-597 doi:10.1002/jimd.12125.
PMID: 31095747
3
[Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review].
Lu H, Lu H, Vaucher J, et al.
La Revue de medecine interne 2019; (40(1)):20-27 doi:10.1016/j.revmed.2018.06.005.
PMID: 30031565
4
Whole exome sequencing identifies a new mutation in the SLC19A2 gene leading to thiamine-responsive megaloblastic anemia in an Egyptian family.
Amr K, Pawlikowska P, Aoufouchi S, et al.
Molecular genetics & genomic medicine 2019; (7(7)):e00777 doi:10.1002/mgg3.777.
PMID: 31144472
5
An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.
Gurzhikhanova M, Fomenko S, Chekanov N, et al.
International journal of molecular sciences 2026; (27(14)) doi:10.3390/ijms27146274.
PMID: 42511616
6
Whole-Exome Sequencing Revealed a Pathogenic Nonsense Variant in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia.
Mohsen-Pour N, Naderi N, Ghasemi S, et al.
Laboratory medicine 2022; (53(6)):640-650 doi:10.1093/labmed/lmac040.
PMID: 35686496
7
A Novel Mutation of SLC19A2 in a Chinese Zhuang Ethnic Family with Thiamine-Responsive Megaloblastic Anemia.
Xian X, Liao L, Shu W, et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; (47(5)):1989-1997 doi:10.1159/000491467.
PMID: 29969779
8
Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm.
Klötzer C, Schnabel F, Kubasch AS, et al.
Acta haematologica 2025; (148(4)):380-385 doi:10.1159/000542286.
PMID: 39467528
9
Thiamine Responsive Megaloblastic Anaemia, Diabetes Mellitus and Sensorineural Hearing Loss in a Child.
Khurshid A, Fatimah S, Altaf C, et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2018; (28(9)):S169-S171 doi:10.29271/jcpsp.2018.09.S169.
PMID: 30173687
10
Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes.
Jungtrakoon P, Shirakawa J, Buranasupkajorn P, et al.
Diabetes 2019; (68(5)):1084-1093 doi:10.2337/db17-0821.
PMID: 30833467
11
4-phenylbutyric acid attenuates diabetes mellitus secondary to thiamine-responsive megaloblastic anaemia syndrome by modulating endoplasmic reticulum stress.
Qin Y, Zhang X, Ye Y, et al.
Endokrynologia Polska 2025; (76(1)):108-115 doi:10.5603/ep.101404.
PMID: 40071807
12
First 2 cases with thiamine-responsive megaloblastic anemia in the Czech Republic, a rare form of monogenic diabetes mellitus: a novel mutation in the thiamine transporter SLC19A2 gene-intron 1 mutation c.204+2T>G.
Pomahačová R, Zamboryová J, Sýkora J, et al.
Pediatric diabetes 2017; (18(8)):844-847 doi:10.1111/pedi.12479.
PMID: 28004468
13
An Adult Case of Thiamine-Sensitive Megaloblastic Anemia Syndrome Accidentally Diagnosed Myelodysplastic Syndrome.
Kutlucan A
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(6)):S13-S15 doi:10.29271/jcpsp.2019.06.S13.
PMID: 31142407
14
Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report.
Katipoğlu N, Karapinar TH, Demir K, et al.
Archivos argentinos de pediatria 2017; (115(3)):e153-e156 doi:10.5546/aap.2017.eng.e153.
PMID: 28504500
15
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.
Habeb AM, Flanagan SE, Zulali MA, et al.
Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.
PMID: 29450569
16
Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia.
Zhang S, Qiao Y, Wang Z, et al.
Clinica chimica acta; international journal of clinical chemistry 2021; (516()):157-168 doi:10.1016/j.cca.2021.01.025.
PMID: 33571483
17
Thiamine-Responsive Megaloblastic Anaemia With Hypothyroidism, A Puzzling Association.
Rai VR, Ibrahim MN, Javed MN, et al.
Journal of Ayub Medical College, Abbottabad : JAMC 2023; (35(Suppl 1)(4)):S804-S806 doi:10.55519/JAMC-S4-12486.
PMID: 38406914
18
Relapse of rare diseases during COVID-19 pandemic: bicytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Nouira N, Mansouri R, Tlili R, et al.
The Pan African medical journal 2020; (35(Suppl 2)):139 doi:10.11604/pamj.supp.2020.35.139.25368.
PMID: 33193954
19
Pancytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Moulin V, Grandoni F, Castioni J, Lu H
BMJ case reports 2018; (2018()) doi:10.1136/bcr-2018-225035.
PMID: 29903777
20
Rogers Syndrome, an Uncommon Cause of Megaloblastic Anemia: A Case Series.
Roshan R, Mehboob M, Latif R, et al.
Advanced biomedical research 2026; (15()):24 doi:10.4103/abr.abr_16_24.
PMID: 42427428

This page explains TRMA biology, possible misdiagnoses, and diagnostic testing for informational purposes only and does not constitute medical advice. A hematologist, geneticist, or metabolic specialist should interpret your child's results and guide care.